Alterity has secured the worldwide exclusive right to patented technology to develop and commercialise therapies that re-sensitise bacteria to antibiotics
If validated, the discovery by St Jude scientists could offer real tools to deal with hyperinflammatory immune responses, one of the leading causes of death in Covid-19 infections